Urogen Pharma (NASDAQ:URGN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Urogen Pharma (NASDAQ:URGN) have earned a consensus recommendation of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $39.50.

A number of brokerages have commented on URGN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. HC Wainwright reiterated a “buy” rating and issued a $45.00 price objective on shares of Urogen Pharma in a research report on Wednesday, June 3rd. Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a research report on Tuesday, June 2nd. D. Boral Capital reissued a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a report on Tuesday, March 31st. Finally, Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a report on Friday, April 24th.

Insider Activity

In other news, insider Mark Schoenberg sold 5,222 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $27.30, for a total value of $142,560.60. Following the completion of the transaction, the insider directly owned 139,763 shares of the company’s stock, valued at approximately $3,815,529.90. This represents a 3.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 4.70% of the company’s stock.

Hedge Funds Weigh In On Urogen Pharma

Hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Urogen Pharma by 27.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after buying an additional 486 shares in the last quarter. State of Wyoming acquired a new position in shares of Urogen Pharma in the 3rd quarter worth approximately $66,000. Russell Investments Group Ltd. raised its holdings in shares of Urogen Pharma by 1,594.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after buying an additional 3,125 shares in the last quarter. Osaic Holdings Inc. raised its holdings in shares of Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after buying an additional 3,070 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Urogen Pharma by 422.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock worth $94,000 after buying an additional 5,571 shares in the last quarter. 91.29% of the stock is owned by institutional investors and hedge funds.

Urogen Pharma Trading Up 0.7%

Shares of URGN stock opened at $29.72 on Tuesday. The stock has a 50 day moving average of $25.72 and a two-hundred day moving average of $22.87. Urogen Pharma has a 12 month low of $11.51 and a 12 month high of $32.37. The company has a market capitalization of $1.45 billion, a P/E ratio of -10.81 and a beta of 1.59.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01. The firm had revenue of $50.96 million during the quarter, compared to the consensus estimate of $44.83 million. Sell-side analysts predict that Urogen Pharma will post -0.98 earnings per share for the current fiscal year.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.